{"id":"W3213981466","doi":"10.1182/blood-2021-148155","title":"Majic: A Phase 3 Prospective, Multicenter, Randomized, Open-Label Trial of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Venetoclax; Obinutuzumab; Ibrutinib; Medicine; Chronic lymphocytic leukemia; IGHV@; Internal medicine; Neutropenia; Tumor lysis syndrome; Oncology; Regimen; Leukemia; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001826099,0.001146713,0.004215512,0.0006010158,0.0002129605,0.0002478993,0.001411319,0.0008018745,0.0005000113],"category_scores_gemma":[0.004720504,0.0009858609,0.0005862594,0.002349203,0.0008876388,0.0003441828,0.00132804,0.0005696492,0.0001861866],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.6458672,"about_ca_system_score_gemma":0.5878464,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01437109,"about_ca_topic_score_gemma":0.002569533,"domain_scores_codex":[0.9905462,0.001152443,0.002487013,0.002078515,0.001551834,0.002184045],"domain_scores_gemma":[0.9928156,0.002327343,0.0008532887,0.002347564,0.0008005337,0.0008557034],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9752084,0.001454711,0.000008007287,0.001770914,0.002259218,0.008436423,0.001085641,0.003734043,0.00213298,0.0001579883,0.0001621598,0.003589533],"study_design_scores_gemma":[0.7254347,0.00489794,0.00000902457,0.001809951,0.001874329,0.001147216,0.0002005074,0.2420061,0.02143242,0.00003147321,0.0004861838,0.0006701213],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9760193,0.005385364,0.00004687061,0.0000291208,0.0008945775,0.01463559,0.00008871088,0.0002198712,0.002680565],"genre_scores_gemma":[0.987175,0.002642975,0.001470923,0.0001272487,0.0006483425,0.002758073,0.0003642518,0.0002879516,0.00452523],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2497737,"threshold_uncertainty_score":0.9992592,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06305773727376265,"score_gpt":0.3625124696844897,"score_spread":0.2994547324107271,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}